A Decision-Analytic Protocol for Evaluating a Two-Cutoff Staged Diagnostic Strategy in Early Alzheimer's Disease
American Journal of Capstone Research · 2026
DOI: 10.70251/147 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift American Journal of Capstone Research, 2026. Verfasst von Riya Ravikumar. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease affects millions of older adults and imposes an immense and rising economic burden, driven in part by the cost of diagnosis itself (Alzheimer's Association, 2025). As Alzheimer's disease is increasingly defined biologically, current diagnostic frameworks must specify how lower-cost blood tests, including plasma phosphorylated tau 217 (p-tau217), should be sequenced relative to more expensive confirmatory procedures, including amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) testing (Jack et al., 2024). This protocol proposes a decision-analytic model, built on data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), to compare four diagnostic pathways for symptomatic patients with mild cognitive impairment (MCI) or early cognitive decline: universal confirmatory testing; cognition-plus-magnetic resonance imaging (MRI) triage; plasma-first single-cutoff triage; and a hybrid staged pathway that combines clinical and cognitive measures, MRI, and a two-cutoff predicted-risk strategy incorporating plasma p-tau217 to reserve confirmatory testing for indeterminate cases. The core design goal is to evaluate whether an allocation rule can minimize avoidable use of PET or CSF confirmation while preserving acceptable identification of amyloid-positive disease, particularly when confirmatory-test capacity is limited. Rather than testing whether plasma p-tau217 detects amyloid pathology, a question the current literature largely answers, this protocol asks how a resource-constrained health system should deploy the biomarker. The proposed framework has not been implemented or validated, and this methodology report presents no empirical results. The intended contribution is a reproducible framework for developing and evaluating diagnostic decision rules using ADNI data to assess how to allocate confirmatory testing more efficiently, with direct relevance to coverage, workflow, and diagnostic-pathway design in early Alzheimer's disease care.
Zitieren
APA
Ravikumar, R. (2026). A Decision-Analytic Protocol for Evaluating a Two-Cutoff Staged Diagnostic Strategy in Early Alzheimer's Disease. American Journal of Capstone Research. https://doi.org/10.70251/147
Vancouver
Ravikumar R. A Decision-Analytic Protocol for Evaluating a Two-Cutoff Staged Diagnostic Strategy in Early Alzheimer's Disease. American Journal of Capstone Research. 2026. doi:10.70251/147
BibTeX
@article{Ravikumar2026,
author = {Ravikumar, Riya},
title = {A Decision-Analytic Protocol for Evaluating a Two-Cutoff Staged Diagnostic Strategy in Early Alzheimer's Disease},
journal = {American Journal of Capstone Research},
year = {2026},
doi = {10.70251/147}
}
EUVIMED